Characterizing Diagnostic Delays in Metachromatic Leukodystrophy: A Real‐World Data Approach
Journal of Inherited Metabolic Disease · 2025-07 · 48 (4)
DOI: 10.1002/jimd.70049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 02.06.2025. Verfasst von Ali Mohajer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Qral Group, New Jersey, New Jersey, USA. Hauptthemen laut MEDLINE: Leukodystrophy, Metachromatic, Delayed Diagnosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Neurodegeneration in metachromatic leukodystrophy (MLD) may be preceded by systemic complications. Characterization of these features is critical to define barriers to early diagnosis and treatment eligibility for gene therapy. We utilized medical billing (claims) datasets and a natural history study to capture pre‐diagnosis MLD‐related events. MLD‐related events (ICD‐10‐CM codes) were aggregated into system‐based diagnosis clusters, and time to MLD diagnosis (TTD) computed for each organ‐system diagnosis cluster. Differences in TTD distribution, instantaneous diagnosis hazard, and survival to MLD diagnosis were compared by sex and payor type. TTD and regression from onset of first symptoms were described using median and inter‐quartile range. The claims dataset identified 174 MLD cases (diagnosis ≤ 6 years old) with 14 diagnosed within the first year of life. General neurologic concerns ( n = 138; median 257 days pre‐diagnosis), gastrointestinal ( n = 137; 231 days), seizures ( n = 48; 236 days), ophthalmologic ( n = 46; 362 days), and language‐related events ( n = 41; 267 days) were common. Time to MLD diagnosis from onset of prodromal clusters was longer for children with non‐commercial insurance: most prominent with seizures (survival logrank p value < 0.02) and non‐degenerative neurological symptoms (survival logrank p value < 0.04). Similar findings were noted in our analysis of a second claims dataset. The natural history cohort demonstrated a similar pattern of prodromal disease features and delayed diagnosis. This study defines barriers to MLD diagnosis and highlights prodromal periods of pre‐regression symptomatology, further supporting the need for early screening in this fatal disorder of childhood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Qral Group, New Jersey, New Jersey, USA.
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Orchard Therapeutics, London, UK.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Anjana Sevagamoorthy
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Mohajer, A., Sevagamoorthy, A., Bean, K., Mutua, S., Pang, F., & Adang, L. A. (2025). Characterizing Diagnostic Delays in Metachromatic Leukodystrophy: A Real‐World Data Approach. Journal of Inherited Metabolic Disease, 48(4). https://doi.org/10.1002/jimd.70049
Vancouver
Mohajer A, Sevagamoorthy A, Bean K, Mutua S, Pang F, Adang LA. Characterizing Diagnostic Delays in Metachromatic Leukodystrophy: A Real‐World Data Approach. Journal of Inherited Metabolic Disease. 2025;48(4). doi:10.1002/jimd.70049
BibTeX
@article{Mohajer2025,
author = {Mohajer, Ali and Sevagamoorthy, Anjana and Bean, Karen and Mutua, Sylvia and Pang, Francis and Adang, Laura Ann},
title = {Characterizing Diagnostic Delays in Metachromatic Leukodystrophy: A Real‐World Data Approach},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {4},
doi = {10.1002/jimd.70049}
}
EUVIMED